[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI0994872T1 - - Google Patents

Info

Publication number
SI0994872T1
SI0994872T1 SI9730138T SI9730138T SI0994872T1 SI 0994872 T1 SI0994872 T1 SI 0994872T1 SI 9730138 T SI9730138 T SI 9730138T SI 9730138 T SI9730138 T SI 9730138T SI 0994872 T1 SI0994872 T1 SI 0994872T1
Authority
SI
Slovenia
Prior art keywords
alkyl
halo
alkoxy
trifluoroalkyl
alkynyl
Prior art date
Application number
SI9730138T
Other languages
English (en)
Inventor
Franciscus Bernardus Benneker
Dalen Frans Van
Jacobus Maria Lemmens
Theodorus Hendricus Ant Peters
Frantisek Picha
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26647319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0994872(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of SI0994872T1 publication Critical patent/SI0994872T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI9730138T 1997-06-10 1997-06-10 SI0994872T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NL1997/000328 WO1998056787A1 (de) 1997-06-10 1997-06-10 4-Phenylpiperidin-Derivate
US08/872,023 US5874447A (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds for treating depression
EP97926276A EP0994872B9 (de) 1997-06-10 1997-06-10 4-phenylpiperidin-derivate

Publications (1)

Publication Number Publication Date
SI0994872T1 true SI0994872T1 (de) 2001-08-31

Family

ID=26647319

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730138T SI0994872T1 (de) 1997-06-10 1997-06-10

Country Status (26)

Country Link
US (4) US5874447A (de)
EP (2) EP0994872B9 (de)
JP (1) JP2002503248A (de)
KR (1) KR100543614B1 (de)
AT (1) ATE200781T1 (de)
AU (1) AU3108097A (de)
BG (1) BG64315B1 (de)
BR (1) BR9714787A (de)
CA (1) CA2293247C (de)
CZ (1) CZ295301B6 (de)
DE (2) DE69704679T2 (de)
DK (1) DK0994872T3 (de)
EE (2) EE03970B1 (de)
ES (1) ES2155995T3 (de)
GR (1) GR3035784T3 (de)
HK (1) HK1027352A1 (de)
HU (1) HUP0003141A3 (de)
IL (1) IL133366A (de)
IS (2) IS1927B (de)
NO (3) NO317371B1 (de)
PL (1) PL188450B1 (de)
PT (1) PT994872E (de)
SI (1) SI0994872T1 (de)
SK (1) SK283394B6 (de)
TR (2) TR200201156T2 (de)
WO (1) WO1998056787A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
EP1073652A1 (de) * 1998-04-09 2001-02-07 Smithkline Beecham Plc Paroxetin-maleat
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US20010023252A1 (en) * 1998-07-02 2001-09-20 Smithkline Beecham Plc Novel compound
AU724845B3 (en) * 1998-07-02 2000-09-28 Smithkline Beecham Plc Novel compound
WO2000008016A1 (en) * 1998-08-08 2000-02-17 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9828781D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828779D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828780D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) * 1999-06-22 2000-12-28 Smithkline Beecham P.L.C. Pharmaceutical composition comprising a salt of paroxetine
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
CA2341984A1 (en) * 1999-07-01 2001-01-11 Paolo Mascagni Complexes of paroxetine, with cyclodextrines or cyclodextrin derivatives
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
EP1280775A1 (de) * 2000-05-12 2003-02-05 Synthon B.V. Tosylsalzen von 4-(p-fluorophenyl)-piperidine-3-carbinolen
ES2209876T3 (es) * 2000-05-12 2004-07-01 Synthon B.V. Compuestos de piperidina y procedimiento para su preparacion.
CA2418038A1 (en) * 2000-08-28 2002-03-07 Synthon B.V. Paroxetine compositions and processes for making the same
AU2001286232A1 (en) * 2000-09-14 2002-03-26 Asahi Glass Company, Limited Process for producing paroxetine salt containing substantially no organic solvent
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
WO2002085360A1 (en) * 2001-04-25 2002-10-31 Pentech Pharmaceuticals, Inc. Optimized procedures for the manufacture of paroxetine salts
CA2457382A1 (en) * 2001-06-13 2002-12-19 Teva Pharmaceutical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
EP1412350A1 (de) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetin isethionatsalz, herstellungsverfahren und anwendung bei der behandlung von depression
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AR039163A1 (es) * 2002-03-28 2005-02-09 Synthon Bv Besilato de venlafaxina
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
CN101273024A (zh) * 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
AU2006315684A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
EP2200997B9 (de) 2007-09-13 2016-01-13 Concert Pharmaceuticals Inc. Synthese deuterierter Benzodioxole
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
AR089837A1 (es) * 2012-01-31 2014-09-17 Eisai R&D Man Co Ltd Derivado de paroxetina
EP2844346B1 (de) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmazeutische zusammensetzungen für eine kombinationstherapie
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT99678B (de) * 1921-09-21 1925-04-10 Hoechst Ag Verfahren zur Darstellung arzneilich wirksamer Quecksilberverbindungen.
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (de) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidinderivate mit gastro-intestinaler Wirkung
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223403B1 (de) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel
US5258388A (en) 1986-03-17 1993-11-02 University Of Florida Anticholinergic compounds, compositions and methods of treatment
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
EP0558679A1 (de) 1990-11-24 1993-09-08 BEECHAM GROUP plc Verwendung von paroxetin zur behandlung von seniler demenz, bulimia, migräne oder anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (de) * 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
JPH08220486A (ja) * 1994-12-14 1996-08-30 Kato Kogei:Kk 眼鏡フレーム
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
GB2297550C2 (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
EP0818990A1 (de) * 1995-04-03 1998-01-21 Abbott Laboratories Homogene mischungen aus niedrigschmelzenden arzneistoffen und additiven zur verzögerten wirkstoffeingabe
HUP9900318A3 (en) * 1995-05-17 2001-09-28 Novo Nordisk As Process for preparing 4-aryl-piperidine derivatives
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (de) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Verfahren zur Trocknung von Paroxetinhydrochlorid
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
HK1027352A1 (en) 2001-01-12
CZ429599A3 (cs) 2000-04-12
NO317371B1 (no) 2004-10-18
PT994872E (pt) 2001-09-28
EP0994872B9 (de) 2001-12-05
KR100543614B1 (ko) 2006-01-20
IS1927B (is) 2004-04-15
EP1078925A1 (de) 2001-02-28
BG103980A (en) 2000-07-31
TR199903025T2 (xx) 2000-07-21
US5874447A (en) 1999-02-23
EP0994872B1 (de) 2001-04-25
BR9714787A (pt) 2000-07-18
IS7098A (is) 2004-01-08
US7598271B1 (en) 2009-10-06
CZ295301B6 (cs) 2005-07-13
IL133366A (en) 2005-11-20
DE69704679T2 (de) 2001-09-13
EP0994872A1 (de) 2000-04-26
SK283394B6 (sk) 2003-07-01
ATE200781T1 (de) 2001-05-15
IL133366A0 (en) 2001-04-30
HUP0003141A3 (en) 2001-04-28
NO995455L (no) 2000-02-09
BG64315B1 (bg) 2004-09-30
ES2155995T3 (es) 2001-06-01
SK161999A3 (en) 2000-08-14
NO20033765L (no) 2000-02-09
DE69704679D1 (de) 2001-05-31
TR200201156T2 (tr) 2002-07-22
CA2293247A1 (en) 1998-12-17
AU3108097A (en) 1998-12-30
PL336895A1 (en) 2000-07-17
IS5249A (is) 1999-11-16
KR20010013615A (de) 2001-02-26
DK0994872T3 (da) 2001-05-28
JP2002503248A (ja) 2002-01-29
US6900327B2 (en) 2005-05-31
NO20033765D0 (no) 2003-08-25
WO1998056787A1 (de) 1998-12-17
EE9900570A (et) 2000-08-15
PL188450B1 (pl) 2005-02-28
US20090326233A1 (en) 2009-12-31
CA2293247C (en) 2005-04-12
DE29724281U1 (de) 2000-08-10
HUP0003141A2 (en) 2001-03-28
NO20033766L (no) 2000-02-09
GR3035784T3 (en) 2001-07-31
NO20033766D0 (no) 2003-08-25
US20010031767A1 (en) 2001-10-18
EE03970B1 (et) 2003-02-17
EE200200633A (et) 2003-02-17
NO995455D0 (no) 1999-11-08

Similar Documents

Publication Publication Date Title
HK1027352A1 (en) 4-phenylpiperidine compounds
TW334435B (en) Bicyclic amines
GB2398781B (en) Kinase inhibitors
GR3003920T3 (de)
GB9801690D0 (en) Therapeutic agents
MY125359A (en) Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods.
YU82303A (sh) Analozi nociceptina
TW351718B (en) Acylated aminoalkanimidazoles and -triazoles
AP2001002045A0 (en) FKBP inhibitors.
ZA97844B (en) Fungicides.
PL349933A1 (en) Novel compounds beta-hydroxyalylamides, method of obtaining them and their application
NZ333854A (en) Intermediates for the preparation of 2-imidazoline-5-ones
GB9811050D0 (en) Pyrazoles
WO2000034272A3 (de) 3-(heterocyclyl)-benzoylpyrazol-derivate
WO2002058632A3 (en) Primary intermediates for oxidative coloration of hair
UA70917C2 (uk) Похідні оксадіазину, інсектицидна композиція та спосіб боротьби з комахами
GR3007320T3 (de)
UA42694C2 (uk) ПОХІДНІ 1-{[<font face="Symbol">a</font>-ЦИКЛОПРОПІЛ-<font face="Symbol">a</font>-(ЗАМІЩЕНИЙ ОКСИ)-О-ТОЛІЛ]-СУЛЬФАМОЇЛ}-3-(4,6-ДИМЕТОКСИ-2-ПІРИМІДИНІЛ) СЕЧОВИНИ, СПОСІБ ПРИГНІЧЕННЯ НЕБАЖАНИХ ВИДІВ РОСЛИН ТА ГЕРБІЦИДНА КОМПОЗИЦІЯ
IT1306399B1 (it) Foratrice per cave di componenti curvi o inclinati di persiane.
GB9111842D0 (en) Hole cutter,blockwork/brickwork
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.